FDA Approves Once-Weekly Sogroya for the Treatment of Children Living with Growth Hormone Deficiency

PLAINSBORO, NJ, April 28, 2023– Novo Nordisk announced today that the U.S. Food and Drug Administration (FDA) has approved a new indication for Sogroya® (somapacitan-beco) injection 5 mg, 10 mg, or 15 mg for the treatment of children aged...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news